Social value of statins merits actions to broaden treatment, improve adherence, study finds
News
Article
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
Social value of statins merits actions to broaden treatment, improve adherence, study finds
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
FDA to Hold Ad Comm Meeting for Rexulti in PTSD
The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, originally planned for Feb. 8, 2025, will be delayed.
Read More
Bayer Submits Supplemental NDA for Kerendia in Heart Failure
Kerenida is currently approved to slow the progression of chronic kidney disease associated with type 2 diabetes.
Read More
FDA Requires Guillain-Barré Warning for Abrysvo and Arexvy
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus continue to outweigh their risks.
Read More
IBX Excludes Coverage of Drugs with Accelerated Approvals for 18 Months
Effective Jan. 1, 2025, Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an accelerated approval based on a surrogate endpoint.
Read More
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly therapy and the first specifically approved for cardiomyopathy in patients with Duchenne muscular dystrophy.
Read More
FDA Sets Goal Date for Ovarian Cancer Combination
FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat patients with recurrent low-grade serous ovarian cancer.
Read More
FDA to Hold Ad Comm Meeting for Rexulti in PTSD
The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, originally planned for Feb. 8, 2025, will be delayed.
Read More
Bayer Submits Supplemental NDA for Kerendia in Heart Failure
Kerenida is currently approved to slow the progression of chronic kidney disease associated with type 2 diabetes.
Read More
FDA Requires Guillain-Barré Warning for Abrysvo and Arexvy
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus continue to outweigh their risks.
Read More
IBX Excludes Coverage of Drugs with Accelerated Approvals for 18 Months
Effective Jan. 1, 2025, Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an accelerated approval based on a surrogate endpoint.
Read More
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly therapy and the first specifically approved for cardiomyopathy in patients with Duchenne muscular dystrophy.
Read More
FDA Sets Goal Date for Ovarian Cancer Combination
FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat patients with recurrent low-grade serous ovarian cancer.
Read More